Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

170

Enrollment

OTHER

Sponsor class

Stopped Interim Analysis

Conditions

Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Follicular T-Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Etoposide
DRUG: Duvelisib
DRUG: Oral azacitidine

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]